Clinical trials: Aromatase Inhibitors
Breast Cancer
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant and exemestane, anastrozole, or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells and by…
- Trial name
- NCT00688194
- Testing
- anastrozole, exemestane, fulvestrant
- Where
- Italy
- Volunteers
- 396 people
- Sponsor
- Gruppo Italiano Mammella (GIM)
Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
This phase II clinical trial studies how well fulvestrant and palbociclib works in treating older patients with breast cancer that responds to hormone treatment (hormone responsive) that cannot be removed by surgery.
- Conditions
- Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT02760030
- Testing
- Fulvestrant, Laboratory Biomarker Analysis, Palbociclib
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00573755
- Testing
- anastrozole, exemestane, letrozole
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Estrogen Receptor Positive Breast Cancer, Breast Cancer
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens.
- Trial name
- REVIVE (NCT01984138)
- Testing
- ESTRING, Replens, Vagifem
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Polly A. Niravath, MD
Luminal B/HER2-negative Breast Cancer
Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)
Evaluate the efficacy and safety of Dalpiciclib combined with aromatase inhibitors as a neoadjuvant therapy in Luminal B/HER2-negative breast cancer.
- Trial name
- NCT05640778
- Testing
- Dalpiciclib combined with aromatase inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Advanced Breast Cancer
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
This study aimed at evaluating the safety and efficacy of everolimus plus exemestane in Chinese postmenopausal women with ER+ HER2- locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on…
- Trial name
- BOLERO-5 (NCT03312738)
- Testing
- Everolimus, Exemestane
- Where
- 15 sites in China
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors
A single--blind, randomized, placebo--controlled phase II study to evaluate the impact of oral bisphosphonate treatment on bone mineral density in osteopenic women receiving aromatase inhibitors as adjuvant treatment.
- Trial name
- BONADIUV (NCT02616744)
- Testing
- Ibandronic acid
- Where
- Italy
- Volunteers
- 171 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Postmenopausal Women With Advanced Breast Cancer
Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment
Safety and efficacy of letrozole 2.5 mg/day monotherapy as second-line endocrine therapy in postmenopausal patients with advanced breast cancer who received previous anti-estrogen treatment To investigate changes in blood drug…
- Trial name
- NCT00237198
- Testing
- Letrozole
- Where
- 24 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00423917
- Testing
- bevacizumab, fulvestrant
- Where
- 205 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
500mg Fulvestrant Versus Exemestane in MBC
500mg Fulvestrant versus Exemestane in MBC
- Trial name
- NCT03575260
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Breast Cancer
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00382070
- Testing
- Letrozole
- Where
- 806 sites in United States, Canada and 1 more
- Volunteers
- 3,966 people
- Sponsor
- NSABP Foundation Inc
Sexuality
Breast Cancer, Sexuality and Black Cohosh
The purpose of this study is to evaluate the Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen or aromatase inhibitor through questionnaires.
- Trial name
- Cimicifuga (NCT02467686)
- Testing
- WHOQOL questionnaire, FSFI questionnaire, kupperman scale
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Irmandade da Santa Casa de Misericordia de Sao Paulo
Breast Cancer
Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors
This is an observational trial designed to assess prospectively the adherence rate to AIs among women with invasive breast cancer (stages I-III) currently receiving AI adjuvant therapy after standard local and systemic therapy.
- Trial name
- ALPA (NCT03144037)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Breast Cancer
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.
- Trial name
- NCT06307457
- Testing
- Palbociclib in combination with AI
- Where
- Denmark
- Volunteers
- 604 people
- Sponsor
- Pfizer
Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
The purpose of the study is to determine the diagnostic role of ctDNA when used to monitor metastatic breast cancer (MBC) during first-line endocrine therapy.
- Conditions
- Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms, Neoplasms, Breast, Breast Diseases
- Trial name
- MAGNETIC1 (NCT05814224)
- Testing
- Liquid biopsy and CT scan
- Where
- 7 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Breast Cancer, Osteoporosis, Osteopenia
Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor
This study evaluates the efficacy of the probiotic food supplement Vivomixx in the prevention of bone loss occurring in post menopausal women with breast cancer treated with an aromatase inhibitor.
- Trial name
- NCT03518268
- Testing
- Vivomixx
- Volunteers
- 40 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Breast Cancer
Cognitive Sequelae of Adjuvant Endocrine Therapy for the Treatment of Breast Cancer in Older Women
Breast cancer is the most frequently diagnosed cancer in women with the majority receiving an endocrine therapy (ET) in the adjuvant setting.
- Trial name
- NCT02480218
- Testing
- Neuropsychological test battery
- Where
- Canada
- Volunteers
- 47 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer, Menopause
Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer
Aromatase inhibitor therapy is in France the adjuvant reference treatment for postmenopausal women with early-stage breast cancer. This treatment induces bone loss and a higher risk of fractures.
- Conditions
- Breast Cancer, Menopause, Osteopenia
- Trial name
- RISAROS (NCT00859703)
- Testing
- Risedronate
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Adenomyosis of Uterus, Infertility Assisted Reproductive Technology
Does The Addition Of Letrozole To Ultra-Long GnRH Agonists Help Adenomyosis Patients in ART? The AURA Trial
The AURA Trial seeks to improve fertility treatment for women affected by a condition known as adenomyosis. Adenomyosis often leads to heavy menstrual bleeding, pelvic pain, dyspareunia and can make it more difficult to achieve…
- Trial name
- AURA (NCT06985186)
- Testing
- Ultra-Long GnRH Agonists + Letrozole, Ultra-Long GnRH Agonists
- Where
- Spain
- Volunteers
- 162 people
- Sponsor
- University of Palermo
Hypogonadism, Hypogonadotropic, Obesity
Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism
The investigators have preliminary data suggesting that obese patients with hypogonadotropic hypogonadism (HHG) have minimal benefit from testosterone therapy likely because of its conversion to estradiol by the abundant…
- Trial name
- NCT03490513
- Testing
- anastrozole (1 mg/day)
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Baylor College of Medicine